Neumora Therapeutics, Inc. (NMRA)
1.54
+0.04
(+2.67%)
USD |
NASDAQ |
Aug 26, 14:19
Neumora Therapeutics EPS Diluted (Quarterly) : -0.2327 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.2327 |
| March 31, 2026 | -0.2972 |
| December 31, 2025 | -0.3528 |
| September 30, 2025 | -0.3507 |
| June 30, 2025 | -0.3261 |
| March 31, 2025 | -0.4211 |
| December 31, 2024 | -0.3654 |
| September 30, 2024 | -0.4546 |
| June 30, 2024 | -0.3692 |
| March 31, 2024 | -0.3371 |
| Date | Value |
|---|---|
| December 31, 2023 | -0.6846 |
| September 30, 2023 | -0.3473 |
| June 30, 2023 | -0.2537 |
| March 31, 2023 | -0.2344 |
| December 31, 2022 | -0.1852 |
| September 30, 2022 | -0.1931 |
| June 30, 2022 | -0.1999 |
| March 31, 2022 | -0.2833 |
| March 31, 2021 | -0.1007 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Johnson & Johnson | 2.268 |
| Indivior Pharmaceuticals, Inc. | 0.9839 |
| Liquidia Corp. | 0.7369 |
| BioAge Labs, Inc. | -0.582 |
| LB Pharmaceuticals, Inc. | -1.712 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -43.08M |
| Total Expenses (Quarterly) | 43.08M |
| Enterprise Value | 216.69M |
| Earnings Yield | -80.09% |
| Normalized Earnings Yield | -78.68 |